tetano
Editor, Senior Moderator
Int J Infect Dis. 2016 Jan 8. pii: S1201-9712(16)00002-3. doi: 10.1016/j.ijid.2016.01.001. [Epub ahead of print]
[h=1]Virus Susceptibility and Clinical Effectiveness of Anti-influenza Drugs During the 2010-2011 Influenza Season in Russia.[/h] Leneva IA[SUP]1[/SUP], Burtseva EI[SUP]2[/SUP], Yatsyshina SB[SUP]3[/SUP], Fedyakina IT[SUP]2[/SUP], Kirillova ES[SUP]2[/SUP], Selkova EP[SUP]4[/SUP], Osipova E[SUP]5[/SUP], Maleev VV[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antiviral drugs are critical adjuncts to influenza vaccination. Here we determined in vitro susceptibility of influenza A and B viruses isolated in 2010-2011 season in Russia to the neuraminidase inhibitor oseltamivir and the hemagglutinin fusion inhibitor umifenovir. We assessed antiviral potency of these drugs against A(H1N1)pdm09 virus in mice. Importantly, we evaluated clinical effectiveness of oseltamivir and umifenovir in a retrospective study conducted in 26 regions of Russia. All tested viruses (n=36) were susceptible to oseltamivir and umifenovir in vitro. Oseltamivir (10mg/kg/day) and umifenovir (60mg/kg/day) significantly increased (p<0.05) survival of mice challenged with A/California/04/2009 (H1N1)pdm09 virus. Influenza infection was laboratory-confirmed in 442 patients among 1,462 hospitalized patients with acute respiratory infection. Treatment of influenza-infected patients within 48hours of symptoms onset with oseltamivir and umifenovir was associated with a significant (p<0.001) decrease in the duration of illness (2-3 days) and symptoms. Pneumonia was observed in none and 0.3% patients treated with oseltamivir and umifenovir, respectively, compared to 23.7% patients without antiviral therapy (p<0.001). This study provided experimental and clinical evidence of the efficacy of oseltamivir and umifenovir against influenza viruses, representatives of which continue to circulate in post-pandemic seasons.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] influenza; observational study; oseltamivir; susceptibility to antivirals; umifenovir
PMID: 26775570 [PubMed - as supplied by publisher] Free full text
[h=1]Virus Susceptibility and Clinical Effectiveness of Anti-influenza Drugs During the 2010-2011 Influenza Season in Russia.[/h] Leneva IA[SUP]1[/SUP], Burtseva EI[SUP]2[/SUP], Yatsyshina SB[SUP]3[/SUP], Fedyakina IT[SUP]2[/SUP], Kirillova ES[SUP]2[/SUP], Selkova EP[SUP]4[/SUP], Osipova E[SUP]5[/SUP], Maleev VV[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antiviral drugs are critical adjuncts to influenza vaccination. Here we determined in vitro susceptibility of influenza A and B viruses isolated in 2010-2011 season in Russia to the neuraminidase inhibitor oseltamivir and the hemagglutinin fusion inhibitor umifenovir. We assessed antiviral potency of these drugs against A(H1N1)pdm09 virus in mice. Importantly, we evaluated clinical effectiveness of oseltamivir and umifenovir in a retrospective study conducted in 26 regions of Russia. All tested viruses (n=36) were susceptible to oseltamivir and umifenovir in vitro. Oseltamivir (10mg/kg/day) and umifenovir (60mg/kg/day) significantly increased (p<0.05) survival of mice challenged with A/California/04/2009 (H1N1)pdm09 virus. Influenza infection was laboratory-confirmed in 442 patients among 1,462 hospitalized patients with acute respiratory infection. Treatment of influenza-infected patients within 48hours of symptoms onset with oseltamivir and umifenovir was associated with a significant (p<0.001) decrease in the duration of illness (2-3 days) and symptoms. Pneumonia was observed in none and 0.3% patients treated with oseltamivir and umifenovir, respectively, compared to 23.7% patients without antiviral therapy (p<0.001). This study provided experimental and clinical evidence of the efficacy of oseltamivir and umifenovir against influenza viruses, representatives of which continue to circulate in post-pandemic seasons.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] influenza; observational study; oseltamivir; susceptibility to antivirals; umifenovir
PMID: 26775570 [PubMed - as supplied by publisher] Free full text